Josh Tumen and Paul C. Ferland contributed the Expert Analysis “Defining All-Risk: Despite $30M Loss, Loose Bolt Not 'Damage'” for Law360. In the article, Josh and Paul provide a brief overview of AMAG Pharmaceuticals, along with general practical guidance for determining whether policyholders' claimed damages satisfy insuring agreements and fit within the scope of coverage.

To read the full article, click here.